I tend to agree and you have to let it play out. Dr J has previously stated “he also wants what is fair to shareholders.” My gut (informed by interviews with Dr. Jay or direct audio communications with shareholders) says he is the antithesis of the Machiavellian kleptocrat. There are two prime impulses that are moving his actions and this is not my thinking, it is Dr Jay telling us how he thinks: he wants this drug in the hands of clinicians that can do good with it (he is first a patient advocate), while also fairly rewarding shareholders who are helping further that mission.